Edition:
United States

People: Acceleron Pharma Inc (XLRN.OQ)

XLRN.OQ on NASDAQ Stock Exchange Global Market

47.62USD
14 Aug 2018
Change (% chg)

-- (--)
Prev Close
$47.62
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
122,503
52-wk High
$50.00
52-wk Low
$32.48

Zeldin, Robert 

Mr. Robert K. Zeldin is Chief Medical Officer of the Company. As a member of the Executive Committee at Ablynx, Dr. Zeldin contributed to the development and implementation of the overall corporate strategy. He was responsible for the Medical, Regulatory, Pharmacovigilance, Clinical Operations, Biostatistics, and Data Management functions and led a team of 60. He joined Ablynx from French pharmaceutical firm Stallergenes SA, where he was Senior Vice President and Head of Global Clinical Development. Earlier, he worked for five years at Novartis Pharmaceuticals, the final three as Vice President and U.S. Medical Franchise Head, Respiratory and Dermatology. Dr. Zeldin's career in industry began at Merck, where he spent seven years in progressively strategic roles in worldwide regulatory affairs and clinical development, rising to the position of Senior Director of Clinical Development with responsibility for products in the respiratory, cardiovascular, and infectious disease therapeutic areas.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Francois Nader

245,291

Habib Dable

1,322,310

Kevin McLaughlin

1,570,900

John Quisel

1,692,320

Ravindra Kumar

1,510,260

Sujay Kango

--
As Of  30 Dec 2017